TrialSignal
Clinical trial intelligence report
A Phase 2/3 Double Blinded, Randomized, Placebo-controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02612909
Status
COMPLETED
Phase
PHASE2
Sponsor
Institute of Vaccines and Medical Biologicals, Vietnam
Executive brief
Investment-Ready Snapshot
The study hypothesis was that two 0.5 mL doses of whole virion monovalent A/H5N1 influenza vaccine (IVACFLU-A/H5N1) adjuvanted with alum would be safe and well tolerated in healthy adults, and that at least one of the two doses tested would be immunogenic in 60% or more of the subjects tested.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02612909
Indication
Avian Influenza
Modality
vaccine
Target
IVACFLU-A/H5N1 vaccine, Placebo
Intervention
IVACFLU-A/H5N1 vaccine, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.